ProCE Banner Activity

WCLC 2020: What’s New With Novel Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer

Conference Coverage
Clinical Thought
Expert commentary on the latest information on ADCs in the treatment of non-small-cell lung cancer presented at WCLC 2020.

Released: March 08, 2021

Expiration: March 07, 2022

No longer available for credit.

Share

Faculty

Egbert F. Smit

Egbert F. Smit, MD, PhD

Professor
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands
Department of Thoracic Oncology
Netherlands Cancer Institute
Amsterdam, Netherlands

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Egbert F. Smit, MD, PhD

Professor
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands
Department of Thoracic Oncology
Netherlands Cancer Institute
Amsterdam, Netherlands

Egbert F. Smit, MD, PhD, that he has received funds for research support from AstraZeneca, Daiichi Sankyo, Merck, MSD, and Novartis; consulting fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Lilly, Merck, MSD, and Novartis; fees for non-CME/CE services from Daiichi Sankyo, Lilly, and MSD; and other financial support from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, and Roche/Genentech.